SCHEMBL3282678

SCHEMBL3282678

O=C(O)c1c[nH]c(=O)c2cc(S(=O)(=O)NC3CC3)ccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARG Q86W56 3/20 0.50
▸ HRH1 P35367 1/20 0.49
▸ CCR3 P51677 1/20 0.49
▸ KCNH2 Q12809 1/20 0.49
▸ ALDH1A1 P00352 5/20 0.47
▸ KDM4E B2RXH2 4/20 0.46
▸ LMNA P02545 3/20 0.45
▸ PIK3CG P48736 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ CACNA1B Q00975 1/20 0.45
▸ APBA1 Q02410 1/20 0.45
▸ TDP1 Q9NUW8 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ BRAF P15056 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ RECQL P46063 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ IDH2 P48735 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2923292 0.82 KDM4E (0.50) HRH1CCR3KCNH2KDM4ELMNA
SCHEMBL3243012 0.80 PARG (0.56) PARGHRH1CCR3KCNH2ALDH1A1
SCHEMBL2922360 0.78 KDM4E (0.56) ALDH1A1KDM4EMAPTTDP1KMT2A
SCHEMBL27615576 0.78 KDM4E (0.39) HRH1CCR3KCNH2KDM4EMAPT
SCHEMBL3282624 0.78 KDM4E (0.52) HRH1CCR3KCNH2ALDH1A1KDM4E
SCHEMBL2916302 0.77 KDM4E (0.54) ALDH1A1KDM4ELMNAMAPTTDP1
SCHEMBL2920920 0.77 KDM4E (0.54) HRH1CCR3ALDH1A1KDM4ELMNA
SCHEMBL2922964 0.77 KDM4E (0.54) HRH1CCR3KCNH2KDM4ELMNA
SCHEMBL3242536 0.76 TDP1 (0.53) PARGALDH1A1KDM4ELMNAMAPT
SCHEMBL3249968 0.75 TDP1 (0.54) PARGALDH1A1KDM4ELMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7709500-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-05-04 — — US disclosed
US-7709500-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-05-04 — — US disclosed
US-7709500-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-05-04 — — US disclosed
US-20050107428-A1 Chemical compounds ASTRAZENECA AB (SE) 2005-05-19 — — US disclosed
EP-1478624-A1 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2004-11-24 — — EP disclosed
WO-2003068743-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2003-08-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107428-A1 Chemical compounds CCR10, CCR3, CXCR5 PARG 4707/4885HRH1 33/4885CCR3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback